Game-Changing HIV Prevention: SA Prepares Rollout of Six-Month Injectable Lenacapavir

Lenacapavir represents a fundamental shift from traditional HIV prevention strategies, which have largely relied on daily oral pre-exposure prophylaxis (PrEP) or frequent clinical interventions.

In what is being hailed as one of the most significant breakthroughs in HIV prevention in recent years, South Africa is preparing to roll out Lenacapavir, a long-acting injectable drug that offers six months of protection against HIV per dose, dramatically transforming the country's prevention landscape.

While Health Minister Dr. Aaron Motsoaledi is yet to officially announce the national launch date, the arrival of the first batch of 37,920 doses in early April marks a critical milestone in the country's fight against one of the world's most persistent public health challenges.

A Paradigm Shift: From Daily Pills to Biannual Protection

Lenacapavir represents a fundamental shift from traditional HIV prevention strategies, which have largely relied on daily oral pre-exposure prophylaxis (PrEP) or frequent clinical interventions.

• Dosage: Just two injections per year

• Protection: Continuous six-month coverage per dose

• Drug Type: HIV-1 capsid inhibitor (long-acting antiretroviral)

This innovation directly addresses long-standing barriers such as:

• Pill fatigue

• Stigma associated with daily medication

• Inconsistent adherence

• Frequent clinic visits

Health experts believe that the simplicity, discretion, and convenience of Lenacapavir could significantly improve adherence rates, particularly among high-risk populations.

Targeting the Most Vulnerable Populations

South Africa continues to bear a disproportionate burden of the global HIV epidemic, with women and girls among the hardest hit. The Department of Health has confirmed that the rollout will prioritize:

• Adolescent girls and young women

• Pregnant and breastfeeding women

• Female sex workers

• Men who have sex with men

• Other high-risk populations

The phased rollout will initially cover:

• 23 high-incidence districts

• Across 6 provinces

• Targeting approximately 360 high-performing public clinics

This data-driven, targeted approach is designed to maximize impact and accelerate progress toward epidemic control.

Backed by Science: Near-Perfect Efficacy in Trials

Lenacapavir's global recognition is rooted in strong clinical evidence and World Health Organization (WHO) endorsement.

Key findings from the PURPOSE trials include:

• 100% efficacy among women in one study

• Approximately 96% efficacy among men who have sex with men and transgender women

These results place Lenacapavir among the most effective HIV prevention tools ever developed.

The WHO has now formally recommended the injectable as an additional HIV prevention option, reinforcing its global significance.

Not a Vaccine, But a Powerful Preventive Tool

Authorities have clarified that Lenacapavir is not a vaccine, but a preventive antiretroviral medication.

It is administered via:

• A subcutaneous injection (under the skin)

• Supported by oral tablets during initiation (Days 1 and 2)

Importantly, WHO guidelines confirm that:

• It is safe to continue during pregnancy and breastfeeding for HIV-negative women at risk

• It must be used alongside safe sex practices, including condom use, to prevent other sexually transmitted infections

Addressing Gaps in Existing Prevention Strategies

South Africa's Department of Health has acknowledged persistent challenges in HIV prevention:

• Declining or inconsistent condom usage

• Low adherence to daily oral PrEP

• Social stigma and lifestyle constraints

Lenacapavir is expected to bridge these gaps by offering a user-friendly, long-acting alternative that fits better into real-world conditions.

Part of a Broader, People-Centred Prevention Strategy

The rollout forms part of a broader shift toward integrated, differentiated, and people-centred HIV prevention services.

Officials emphasize that expanding prevention choices is critical to achieving:

• UNAIDS 95% prevention access target

• The long-term goal of ending AIDS as a public health threat

As Dr. Motsoaledi previously noted, expanding the prevention toolkit is essential to reaching populations that existing interventions fail to adequately serve.

A Turning Point in the Global HIV Fight

With its long-acting design, high efficacy, and WHO backing, Lenacapavir is widely regarded as a "game changer" in HIV prevention.

Public health experts believe that, if successfully scaled, the injectable could:

• Significantly reduce new HIV infections

• Improve adherence rates across vulnerable groups

• Enhance privacy and dignity in prevention

• Strengthen global momentum toward ending HIV/AIDS

As South Africa prepares for its rollout, the world will be watching closely—not just for implementation success, but for a blueprint that could reshape HIV prevention globally.